Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Early-stage lung adenocarcinoma alters DNA methylation, mRNA transcription, and protein expression in adjacent tissues, exhibiting either steep changes at the tumor boundaries or shallow changes ...

The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...

According to Nova One Advisor, the global genomics data analysis market size is calculated at USD 7.91 billion in 2025 and is ...

Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating ...

Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...

ATG-022 is a CLDN18.2-targeted ADC with sub-nM affinity and fast internalization. Using a VC-MMAE linker-payload (DAR 4), ATG-022 has demonstrated potent activity across tumors with high, low, and ...

October 15, 2025- (Investorideas.com Newswire), a go-to investing platform covering biotech and medtech stocks releases a news and trading alert for Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene ...

Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.

Most scientific data never fuel the discoveries they should. For every 100 datasets created, around 80 remain in the lab, 20 are shared but rarely reused, fewer than two meet FAIR standards, and only ...